{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2022_00024478", "CSN": null, "TRF": "ORD_1491858_01", "MRN": "48983411", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1219235", "clinicalId": "1220605", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1491858_01", "SampleName": "US1429059.01", "Version": "0", "Sample": {"FM_Id": "ORD_1491858_01", "SampleId": "US1429059.01", "BlockId": "S111-68526E", "TRFNumber": "ORD_1491858_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2022_11_02", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}]}, "TumorPurity": "40", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "M111-10002", "MRN": "48983411", "FullName": "\u5f35\u6625\u7f8e", "FirstName": "Chun Mei", "LastName": "Chang", "SubmittedDiagnosis": "Metastatic carcinoma", "Gender": "Female", "DOB": "1945_04_05", "OrderingMD": "\u5289\u5cfb\u5b87", "OrderingMDId": "109266", "Pathologist": "\u9673\u5fd7\u5b78", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Adnexal mass", "CollDate": "2022_09_30", "ReceivedDate": "2022-11-14 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Carcinoma, NOS"}, "PertinentNegatives": {"PertinentNegative": [{"Gene": "BRCA1"}, {"Gene": "BRCA2"}, {"Gene": "ERBB2"}, {"Gene": "PIK3CA"}]}, "Summaries": {"alterationCount": "8", "clinicalTrialCount": "0", "resistiveCount": "0", "sensitizingCount": "0"}, "VariantProperties": {"VariantProperty": [{"geneName": "CCND2", "isVUS": "true", "variantName": "R22G"}, {"geneName": "KIT", "isVUS": "true", "variantName": "N933S"}, {"geneName": "MAP3K13", "isVUS": "true", "variantName": "R553S"}, {"geneName": "NF1", "isVUS": "true", "variantName": "E2143K"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "CDH1", "Include": "true", "Alterations": {"Alteration": {"Name": "Q23*", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Q23*"}}, "Interpretation": "CDH1 encodes the transmembrane protein E_cadherin, a tumor suppressor that plays an important role in epithelial cell_cell adhesion and tissue morphogenesis (Gumbiner, 2005; 16025097). Loss of E_cadherin expression leads to decreased cellular adhesion and results in cell migration and cancer metastasis (Wong and Gumbiner, 2003; 12810698, Sarri\u00f3 et al., 2003; 12800196, Mastracci et al., 2005; 15696125, Berx and van Roy, 2009; 20457567). Alterations such as seen here may disrupt CDH1 function or expression (Shapiro and Weis, 2009; 20066110, Shiraishi et al., 2005; 16002701, van Roy, 2014; 24442140, Ishiyama et al., 2010; 20371349, Brooks_Wilson et al., 2004; 15235021). CDH1 mutations occur in 46_65% of invasive lobular breast carcinoma cases (Pereira et al., 2016; 27161491, Ciriello et al., 2015; 26451490, Desmedt et al., 2016; 26926684), with CDH1 allelic loss also being common (89_94%)(Ciriello et al., 2015; 26451490, Desmedt et al., 2016; 26926684, Desmedt et al., 2017; 28400203). In contrast, CDH1 alterations have been reported in 2_5% of invasive ductal breast carcinomas (Ciriello et al., 2015; 26451490, Pereira et al., 2016; 27161491). CDH1 inactivation, through mutations, reduced or lost expression, or promoter hypermethylation, has been associated with more advanced tumor stage, poor prognosis or reduced overall survival in a number of solid tumors, including breast cancer (Liu et al., 2016; 27073531, Tang et al., 2012; 21519872, Kashiwagi et al., 2010; 20551954), endometrial cancer (Mell et al., 2004; 15328195, Kim et al., 2002; 12497652), gastric cancer (Corso et al., 2013; 23341533), non_small cell lung carcinoma (Nakata et al., 2006; 16598757), ovarian carcinoma (Faleiro_Rodrigues et al., 2004; 15367415), pancreatic adenocarcinoma (Hong et al., 2011; 21552209), colon cancer (Matsuoka et al., 2011; 21360533, Karamitopoulou et al., 2011; 21233674), cervical squamous cell carcinoma (Li et al., 2016; 27223886), cholangiocarcinoma (Yao et al., 2012; 23091390, Nitta et al., 2014; 25077440), head and neck cancer squamous cell carcinoma (HNSCC) (Misawa et al., 2016; 27027429, Fuji et al., 2014; 24887090), and early stage esophageal squamous cell carcinoma (Lee et al., 2008; 18697202). There are no available therapies to compensate directly for CDH1 mutation or loss or E_cadherin inactivation. Preclinical studies suggest that CDH1 inactivation may confer sensitivity to ROS1 kinase inhibitors such as crizotinib (Bajrami et al., 2018; 29610289, Telford et al., 2015; 25777964). CDH1 inactivation in breast cancer is characteristic of invasive lobular breast carcinoma (Ciriello et al., 2015; 26451490, Harbeck et al., 2019; 31548545). Germline inactivating CDH1 mutations underlie hereditary diffuse gastric cancer (HDGC), an autosomal_dominant cancer susceptibility that is also associated with an increased risk of infiltrating lobular breast cancer (Hansford et al., 2015; 26182300, Desmedt et al., 2016; 26926684, Christgen et al., 2016; 27233940). The cumulative risk of gastric cancer by age 80 is 70% for men and 56% for women; women also have a 42% risk of breast cancer (Hansford et al., 2015; 26182300). In the appropriate clinical context, germline testing of CDH1 is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "MLL2", "Include": "true", "Alterations": {"Alteration": {"Name": "Q3932*", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Q3932*"}}, "Interpretation": "MLL2 encodes an H3K4_specific histone methyltransferase that is involved in the transcriptional response to progesterone signaling (Vicent et al., 2011; 21447625). Germline de novo mutations of MLL2 are responsible for the majority of cases of Kabuki syndrome, a complex and phenotypically distinctive developmental disorder (Hannibal et al., 2011; 21671394). A significant number of inactivating MLL2 alterations have been observed in multiple tumor types, suggesting a tumor suppressor role (Fagan et al.,2019; 31128216). MLL2 alterations are observed in a number of solid tumor contexts (COSMIC, 2022)(Tate et al., 2019; 30371878), and are especially prevalent in lung squamous cell carcinoma (SCC) (Cancer Genome Atlas Research Network et al., 2012; 22960745) and small cell lung carcinoma (SCLC) (Augert et al., 2017; 28007623). MLL2 mutation was found to be an independent prognostic factor of poor PFS and OS in non_small cell lung cancer, but not in SCLC (Ardeshir_Larijani et al., 2018; 29627316). One study reported that MLL2 truncating mutations were more common in recurrent ovary granulosa cell tumors (GCT) compared with primary GCTs (24% [10/42] vs. 3.0% [1/32])(Hillman et al., 2018; 29950560). In a study of esophageal SCC, high MLL2 expression positively correlated with tumor stage, differentiation, and size, and negatively correlated with OS (Abudureheman et al., 2018; 29532228). There are no targeted therapies available to address genomic alterations in MLL2. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). Comprehensive genomic profiling of solid tumors may detect nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSI is extremely rare in breast cancer, reported in 0_1% of cases across studies (Anbazhagan et al., 1999; 10213220, Adem et al., 2003; 14520695, Horimoto et al., 2020; 32449246, Heeke et al., 2020; 32776290, Kurata et al., 2020; 31907878, Sivapiragasam et al., 2020; 33314633). The incidence of MSI is increased in triple_negative breast cancer (Heeke et al., 2020; 32776290, Kurata et al., 2020; 31907878, Sivapiragasam et al., 2020; 33314633) and in tumors with homologous recombination defects, such as mutations in BRCA1/2 (Heeke et al., 2020; 32776290, Sivapiragasam et al., 2020; 33314633). Notably, in Lynch syndrome\u2013related breast cancer, MSI has been reported in 51_85% of cases (Walsh et al., 2010; 20215533, Risinger et al., 1996; 8646682, De Leeuw et al., 2003; 12615735, Shanley et al., 2009; 19123071, Buerki et al., 2012; 22034109, Yee et al., 1994; 8137273). A prospective study of 123 patients with breast cancer treated with chemotherapy reported an increase in the incidence of MSI_H following chemotherapy treatment (from 0% pre_treatment to 19% post_treatment) and a significant association between MSI and tumor recurrence (Kamat et al., 2012; 22928966). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "01", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "01"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD_1_ or PD_L1_targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types (Goodman et al., 2017; 28835386, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). One study reported that invasive lobular carcinoma (ILC) of the breast has a median TMB of 2.7 mutations per megabase (Muts/Mb), with 5.4% of cases harboring TMB \u226520 Muts/Mb (FMI_Chalmers et al., 2017; 28420421). Other studies have found that 8.7_13.6% of breast ILC cases have TMB \u226510 Muts/Mb, with a higher frequency of such elevated TMB levels (17%) in metastatic samples (Barroso_Sousa et al., 2020; 32067680, Chumsri et al., 2020; 32380464). A study of 3,969 patients with breast cancer reported a median TMB of 2.63 mutations per megabase (Muts/Mb), with 5% of cases harboring TMB \u226510 Muts/Mb; median TMB was significantly higher in hormone receptor (HR)_negative and HER2_negative tumors than HR_positive or HER2_positive tumors (Barroso_Sousa et al., 2020; 32067680). The Breast Invasive Carcinoma TCGA analysis reported an average (non_silent) mutation load of 0.84 Muts/Mb for luminal A tumors, 1.38 Muts/Mb for luminal B tumors, 2.05 Muts/Mb for HER2_enriched tumors, and 1.68 Muts/Mb for basal_like tumors (Cancer Genome Atlas Network, 2012; 23000897). In breast cancer, TMB is significantly higher in recurrent versus primary tumors, metastatic versus localized cancers, triple_negative versus HR_positive tumors, and CDH1_mutated versus CDH1_wildtype tumors (Sokol et al., 2019; 30423024, Barroso_Sousa et al., 2020; 32067680, Chumsri et al., 2020; 32380464, Israel et al., 2020; SABCS Abstract PD9_09). Among metastatic tumors, TMB_high samples have been reported more frequently in invasive lobular carcinoma (9_17% of cases, depending on the TMB cutoff to designate TMB_high) than in invasive ductal carcinoma (2_8% of cases, depending on the cutoff), and TMB_high (at either cutoff) has not been observed in papillary carcinoma (Sokol et al., 2019; 30423024, Barroso_Sousa et al., 2020; 32067680, Chumsri et al., 2020; 32380464, Israel et al., 2020; SABCS Abstract PD9_09). Breast carcinoma harbors a median TMB of 3.8 muts/Mb, and 3.1% of cases have high TMB (>20 muts/Mb) (FMI_Chalmers et al., 2017; 28420421). In a large study of patients with breast cancer, hypermutation was more frequently observed in metastatic tumors than in primary tumors (Barroso_Sousa et al., 2020; 32067680). In a study of 14,867 patients with breast cancer, high TMB was associated with older age and metastatic disease but was not significantly associated with PD_L1 positivity using the TMB cutoff of \u226510 Muts/Mb (Chumsri et al., 2020; 32380464). In estrogen receptor_positive breast cancer, increased TMB in tissue samples (>mean of 1.25 Muts/Mb) associated with shorter OS (HR=2.02) in an analysis of the TCGA data (Haricharan et al., 2014; 24839032). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan_tumor studies, increased tissue tumor mutational burden (TMB) was associated with sensitivity to immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947, Ott et al., 2019; 30557521, Cristescu et al., 2022; 35101941, Friedman et al., 2022; 34876409, Sturgill et al., 2022; 35274716). In the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors, significant improvement in ORR was observed for patients with TMB \u226510 Muts/Mb (as measured by this assay) compared with those with TMB <10 Muts/Mb in a large cohort that included multiple tumor types (Marabelle et al., 2020; 32919526); similar findings were observed in the KEYNOTE 028 and 012 trials (Cristescu et al., 2018; 30309915). At the same TMB cutpoint, retrospective analysis of patients with solid tumors treated with any checkpoint inhibitor identified that tissue TMB scores \u2265 10 Muts/Mb were associated with prolonged time to treatment failure compared with scores <10 muts/Mb (HR=0.68) (Sturgill et al., 2022; 35274716). For patients with solid tumors treated with nivolumab plus ipilimumab in the CheckMate 848 trial, improved responses were observed in patients with a tissue TMB \u2265 10 Muts/Mb independent of blood TMB at any cutpoint in matched samples (Schenker at al., 2022; AACR Abstract 7845). However, support for higher TMB thresholds and efficacy was observed in the prospective Phase 2 MyPathway trial of atezolizumab for patients with pan_solid tumors, where improved ORR and DCR was seen in patients with TMB \u2265 16 Muts/Mb than those with TMB \u2265 10 and <16 Muts/Mb (Friedman et al., 2022; 34876409). Similarly, analyses across several solid tumor types reported that patients with higher TMB (defined as \u226516_20 Muts/Mb) achieved greater clinical benefit from PD_1 or PD_L1_targeting monotherapy compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD_1 or PD_L1_targeting agents (Goodman et al., 2017; 28835386).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": null, "References": {"Reference": [{"number": "0", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "1", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "2", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "3", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "4", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "5", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "6", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "7", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "8", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "9", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "10", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "11", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "12", "ReferenceId": "32919526", "FullCitation": "Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526", "Include": "true"}, {"number": "13", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "14", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "15", "ReferenceId": "32067680", "FullCitation": "Barroso_Sousa R, et al. Ann. Oncol. (2020) pmid: 32067680", "Include": "true"}, {"number": "16", "ReferenceId": "32380464", "FullCitation": "Chumsri S, et al. J Natl Compr Canc Netw (2020) pmid: 32380464", "Include": "true"}, {"number": "17", "ReferenceId": "23000897", "FullCitation": "Nature (2012) pmid: 23000897", "Include": "true"}, {"number": "18", "ReferenceId": "30423024", "FullCitation": "Sokol ES, et al. Ann. Oncol. (2019) pmid: 30423024", "Include": "true"}, {"number": "19", "ReferenceId": "24839032", "FullCitation": "Haricharan S, et al. Breast Cancer Res. Treat. (2014) pmid: 24839032", "Include": "true"}, {"number": "20", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "21", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "22", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "23", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "24", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "25", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "26", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "27", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "28", "ReferenceId": "30557521", "FullCitation": "Ott PA, et al. J. Clin. Oncol. (2019) pmid: 30557521", "Include": "true"}, {"number": "29", "ReferenceId": "35101941", "FullCitation": "Cristescu R, et al. J Immunother Cancer (2022) pmid: 35101941", "Include": "true"}, {"number": "30", "ReferenceId": "34876409", "FullCitation": "Friedman CF, et al. Cancer Discov (2022) pmid: 34876409", "Include": "true"}, {"number": "31", "ReferenceId": "35274716", "FullCitation": "Sturgill EG, et al. Oncologist (2022) pmid: 35274716", "Include": "true"}, {"number": "32", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "33", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "34", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "35", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "36", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "37", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "38", "ReferenceId": "10213220", "FullCitation": "Anbazhagan R, et al. Clin. Cancer Res. (1999) pmid: 10213220", "Include": "true"}, {"number": "39", "ReferenceId": "14520695", "FullCitation": "Adem C, et al. Int. J. Cancer (2003) pmid: 14520695", "Include": "true"}, {"number": "40", "ReferenceId": "32449246", "FullCitation": "Horimoto Y, et al. Cancer Sci (2020) pmid: 32449246", "Include": "true"}, {"number": "41", "ReferenceId": "32776290", "FullCitation": "Heeke AL, et al. Breast Cancer Res Treat (2020) pmid: 32776290", "Include": "true"}, {"number": "42", "ReferenceId": "31907878", "FullCitation": "Kurata K, et al. Breast Cancer (2020) pmid: 31907878", "Include": "true"}, {"number": "43", "ReferenceId": "33314633", "FullCitation": "Sivapiragasam A, et al. Cancer Med (2020) pmid: 33314633", "Include": "true"}, {"number": "44", "ReferenceId": "20215533", "FullCitation": "Walsh MD, et al. Clin. Cancer Res. (2010) pmid: 20215533", "Include": "true"}, {"number": "45", "ReferenceId": "8646682", "FullCitation": "Risinger JI, et al. Cancer (1996) pmid: 8646682", "Include": "true"}, {"number": "46", "ReferenceId": "12615735", "FullCitation": "de Leeuw WJ, et al. Cancer Res. (2003) pmid: 12615735", "Include": "true"}, {"number": "47", "ReferenceId": "19123071", "FullCitation": "Shanley S, et al. Fam. Cancer (2009) pmid: 19123071", "Include": "true"}, {"number": "48", "ReferenceId": "22034109", "FullCitation": "Buerki N, et al. Genes Chromosomes Cancer (2012) pmid: 22034109", "Include": "true"}, {"number": "49", "ReferenceId": "8137273", "FullCitation": "Yee CJ, et al. Cancer Res. (1994) pmid: 8137273", "Include": "true"}, {"number": "50", "ReferenceId": "22928966", "FullCitation": "Kamat N, et al. BMC Cancer (2012) pmid: 22928966", "Include": "true"}, {"number": "51", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "52", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "53", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "54", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "55", "ReferenceId": "16025097", "FullCitation": "Nat. Rev. Mol. Cell Biol. (2005) pmid: 16025097", "Include": "true"}, {"number": "56", "ReferenceId": "12810698", "FullCitation": "Wong AS, et al. J. Cell Biol. (2003) pmid: 12810698", "Include": "true"}, {"number": "57", "ReferenceId": "12800196", "FullCitation": "Sarri\u00f3 D, et al. Int. J. Cancer (2003) pmid: 12800196", "Include": "true"}, {"number": "58", "ReferenceId": "15696125", "FullCitation": "Mastracci TL, et al. Mod. Pathol. (2005) pmid: 15696125", "Include": "true"}, {"number": "59", "ReferenceId": "20457567", "FullCitation": "Berx G, et al. Cold Spring Harb Perspect Biol (2009) pmid: 20457567", "Include": "true"}, {"number": "60", "ReferenceId": "20066110", "FullCitation": "Shapiro L, et al. Cold Spring Harb Perspect Biol (2009) pmid: 20066110", "Include": "true"}, {"number": "61", "ReferenceId": "16002701", "FullCitation": "Shiraishi K, et al. J. Immunol. (2005) pmid: 16002701", "Include": "true"}, {"number": "62", "ReferenceId": "24442140", "FullCitation": "Nat. Rev. Cancer (2014) pmid: 24442140", "Include": "true"}, {"number": "63", "ReferenceId": "20371349", "FullCitation": "Ishiyama N, et al. Cell (2010) pmid: 20371349", "Include": "true"}, {"number": "64", "ReferenceId": "15235021", "FullCitation": "Brooks_Wilson AR, et al. J. Med. Genet. (2004) pmid: 15235021", "Include": "true"}, {"number": "65", "ReferenceId": "27161491", "FullCitation": "Pereira B, et al. Nat Commun (2016) pmid: 27161491", "Include": "true"}, {"number": "66", "ReferenceId": "26451490", "FullCitation": "Ciriello G, et al. Cell (2015) pmid: 26451490", "Include": "true"}, {"number": "67", "ReferenceId": "26926684", "FullCitation": "Desmedt C, et al. J. Clin. Oncol. (2016) pmid: 26926684", "Include": "true"}, {"number": "68", "ReferenceId": "28400203", "FullCitation": "Desmedt C, et al. Semin Cancer Biol (2017) pmid: 28400203", "Include": "true"}, {"number": "69", "ReferenceId": "27073531", "FullCitation": "Liu J, et al. Oncol Lett (2016) pmid: 27073531", "Include": "true"}, {"number": "70", "ReferenceId": "21519872", "FullCitation": "Tang D, et al. Med. Oncol. (2012) pmid: 21519872", "Include": "true"}, {"number": "71", "ReferenceId": "20551954", "FullCitation": "Kashiwagi S, et al. Br. J. Cancer (2010) pmid: 20551954", "Include": "true"}, {"number": "72", "ReferenceId": "15328195", "FullCitation": "Mell LK, et al. Clin. Cancer Res. (2004) pmid: 15328195", "Include": "true"}, {"number": "73", "ReferenceId": "12497652", "FullCitation": "Kim YT, et al. Yonsei Med. J. (2002) pmid: 12497652", "Include": "true"}, {"number": "74", "ReferenceId": "23341533", "FullCitation": "Corso G, et al. J. Clin. Oncol. (2013) pmid: 23341533", "Include": "true"}, {"number": "75", "ReferenceId": "16598757", "FullCitation": "Nakata S, et al. Cancer (2006) pmid: 16598757", "Include": "true"}, {"number": "76", "ReferenceId": "15367415", "FullCitation": "Faleiro_Rodrigues C, et al. Ann. Oncol. (2004) pmid: 15367415", "Include": "true"}, {"number": "77", "ReferenceId": "21552209", "FullCitation": "Hong SM, et al. Mod. Pathol. (2011) pmid: 21552209", "Include": "true"}, {"number": "78", "ReferenceId": "21360533", "FullCitation": "Matsuoka T, et al. J Surg Oncol (2011) pmid: 21360533", "Include": "true"}, {"number": "79", "ReferenceId": "21233674", "FullCitation": "Karamitopoulou E, et al. Pathology (2011) pmid: 21233674", "Include": "true"}, {"number": "80", "ReferenceId": "27223886", "FullCitation": "Li B, et al. PLoS ONE (2016) pmid: 27223886", "Include": "true"}, {"number": "81", "ReferenceId": "23091390", "FullCitation": "Yao X, et al. Onco Targets Ther (2012) pmid: 23091390", "Include": "true"}, {"number": "82", "ReferenceId": "25077440", "FullCitation": "Nitta T, et al. Br. J. Cancer (2014) pmid: 25077440", "Include": "true"}, {"number": "83", "ReferenceId": "27027429", "FullCitation": "Misawa K, et al. Oncotarget (2016) pmid: 27027429", "Include": "true"}, {"number": "84", "ReferenceId": "24887090", "FullCitation": "Fujii R, et al. J. Exp. Clin. Cancer Res. (2014) pmid: 24887090", "Include": "true"}, {"number": "85", "ReferenceId": "18697202", "FullCitation": "Lee EJ, et al. Int. J. Cancer (2008) pmid: 18697202", "Include": "true"}, {"number": "86", "ReferenceId": "29610289", "FullCitation": "Bajrami I, et al. Cancer Discov (2018) pmid: 29610289", "Include": "true"}, {"number": "87", "ReferenceId": "25777964", "FullCitation": "Telford BJ, et al. Mol Cancer Ther (2015) pmid: 25777964", "Include": "true"}, {"number": "88", "ReferenceId": "31548545", "FullCitation": "Harbeck N, et al. Nat Rev Dis Primers (2019) pmid: 31548545", "Include": "true"}, {"number": "89", "ReferenceId": "26182300", "FullCitation": "Hansford S, et al. JAMA Oncol (2015) pmid: 26182300", "Include": "true"}, {"number": "90", "ReferenceId": "27233940", "FullCitation": "Christgen M, et al. Pathol. Res. Pract. (2016) pmid: 27233940", "Include": "true"}, {"number": "91", "ReferenceId": "21447625", "FullCitation": "Vicent GP, et al. Genes Dev. (2011) pmid: 21447625", "Include": "true"}, {"number": "92", "ReferenceId": "21671394", "FullCitation": "Hannibal MC, et al. Am. J. Med. Genet. A (2011) pmid: 21671394", "Include": "true"}, {"number": "93", "ReferenceId": "31128216", "FullCitation": "Fagan RJ, et al. Cancer Lett. (2019) pmid: 31128216", "Include": "true"}, {"number": "94", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "95", "ReferenceId": "22960745", "FullCitation": "Nature (2012) pmid: 22960745", "Include": "true"}, {"number": "96", "ReferenceId": "28007623", "FullCitation": "Augert A, et al. J Thorac Oncol (2017) pmid: 28007623", "Include": "true"}, {"number": "97", "ReferenceId": "29627316", "FullCitation": "Ardeshir_Larijani F, et al. Clin Lung Cancer (2018) pmid: 29627316", "Include": "true"}, {"number": "98", "ReferenceId": "29950560", "FullCitation": "Hillman RT, et al. Nat Commun (2018) pmid: 29950560", "Include": "true"}, {"number": "99", "ReferenceId": "29532228", "FullCitation": "Abudureheman A, et al. J. Cancer Res. Clin. Oncol. (2018) pmid: 29532228", "Include": "true"}, {"number": "100", "ReferenceId": "25426837", "FullCitation": "Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837", "Include": "true"}, {"number": "101", "ReferenceId": "25426838", "FullCitation": "Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838", "Include": "true"}, {"number": "102", "ReferenceId": "25326804", "FullCitation": "Xie M, et al. Nat. Med. (2014) pmid: 25326804", "Include": "true"}, {"number": "103", "ReferenceId": "28669404", "FullCitation": "Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404", "Include": "true"}, {"number": "104", "ReferenceId": "29678827", "FullCitation": "Severson EA, et al. Blood (2018) pmid: 29678827", "Include": "true"}, {"number": "105", "ReferenceId": "29420212", "FullCitation": "Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212", "Include": "true"}, {"number": "106", "ReferenceId": "32269342", "FullCitation": "Chabon JJ, et al. Nature (2020) pmid: 32269342", "Include": "true"}, {"number": "107", "ReferenceId": "31768066", "FullCitation": "Razavi P, et al. Nat. Med. (2019) pmid: 31768066", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2022_11_11 17:17:46", "OpName": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "892x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "1 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "BREAST", "disease_ontology": "Breast invasive lobular carcinoma (ILC)", "flowcell_analysis": "2000024452", "gender": "female", "pathology_diagnosis": "Metastatic Carcinoma (from breast lobular carcinoma)", "percent_tumor_nuclei": "40", "pipeline_version": "v3.15.0", "purity_assessment": "20.0", "specimen": "ORD_1491858_01*US1429059.01", "study": "CLINICAL_F1CDx v2", "test_request": "ORD_1491858_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Adnexal mass", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX2", "mean_exon_depth": "904.23", "name": "SQ_US1429059.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.4719", "cds_effect": "1659A>C", "depth": "835", "equivocal": "false", "functional_effect": "missense", "gene": "MAP3K13", "percent_reads": "47.19", "position": "chr3:185190778", "protein_effect": "R553S", "status": "unknown", "strand": "+", "transcript": "NM_004721", "dna_evidence": {"sample": "SQ_US1429059.01_1"}}, {"allele_fraction": "0.4829", "cds_effect": "64C>G", "depth": "673", "equivocal": "false", "functional_effect": "missense", "gene": "CCND2", "percent_reads": "48.29", "position": "chr12:4383270", "protein_effect": "R22G", "status": "unknown", "strand": "+", "transcript": "NM_001759", "dna_evidence": {"sample": "SQ_US1429059.01_1"}}, {"allele_fraction": "0.202", "cds_effect": "67C>T", "depth": "589", "equivocal": "false", "functional_effect": "nonsense", "gene": "CDH1", "percent_reads": "20.2", "position": "chr16:68772218", "protein_effect": "Q23*", "status": "known", "strand": "+", "transcript": "NM_004360", "dna_evidence": {"sample": "SQ_US1429059.01_1"}}, {"allele_fraction": "0.2122", "cds_effect": "11794C>T", "depth": "688", "equivocal": "false", "functional_effect": "nonsense", "gene": "MLL2", "percent_reads": "21.22", "position": "chr12:49426694", "protein_effect": "Q3932*", "status": "likely", "strand": "_", "transcript": "NM_003482", "dna_evidence": {"sample": "SQ_US1429059.01_1"}}, {"allele_fraction": "0.1641", "cds_effect": "6427G>A", "depth": "646", "equivocal": "false", "functional_effect": "missense", "gene": "NF1", "percent_reads": "16.41", "position": "chr17:29663932", "protein_effect": "E2143K", "status": "unknown", "strand": "+", "transcript": "NM_001042492", "dna_evidence": {"sample": "SQ_US1429059.01_1"}}, {"allele_fraction": "0.4378", "cds_effect": "2798A>G", "depth": "715", "equivocal": "false", "functional_effect": "missense", "gene": "KIT", "percent_reads": "43.78", "position": "chr4:55603442", "protein_effect": "N933S", "status": "unknown", "strand": "+", "transcript": "NM_000222", "dna_evidence": {"sample": "SQ_US1429059.01_1"}}]}, "copy_number_alterations": null, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "1.21", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}